Kalaris Therapeutics, Inc. (KLRS)
Healthcare
Biotechnology
3.50 $
+0.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Kalaris Therapeutics, Inc. (KLRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 30.3% of the shares are freely tradable; institutional investors hold 77.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
77.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
8.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
30.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
24Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 54.42 | 12,948,081 | +0.0 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 5.46 | 1,300,000 | +0.0 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 2.94 | 700,000 | +0.0 | 03/31/2026 |
| Alyeska Investment Group, L.P. | 2.41 | 572,687 | +41.9 | 03/31/2026 |
| Siren, L.L.C. | 1.83 | 435,798 | +0.0 | 03/31/2026 |
| Ikarian Capital, LLC | 1.51 | 360,000 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 1.23 | 292,790 | +44.2 | 12/31/2025 |
| Kalehua Capital Management LLC | 1.14 | 271,170 | +93.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 1.07 | 255,348 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 0.74 | 176,727 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.